Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510029 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
A Phase 1 study of Arrhythmia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00510029: Completed Phase 1 study of Arrhythmia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00510029 is a Phase 1 study of Arrhythmia that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 72 participants, below the 1,884-participant average among 16 other Arrhythmia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00510029, a Phase 1 study of Arrhythmia, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.
Conditions Studied
Interventions
- DRUG GAP-134
Study Locations (1)
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00510029 record still lists
NCT00510029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,884-participant average among 16 other Arrhythmia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Arrhythmia appearing as the primary indexed condition, and to 1 intervention - of which GAP-134 is the first listed.
NCT00510029 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00510029 about?
NCT00510029 is a clinical study titled "Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously". The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.
What is the current status of trial NCT00510029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2007-09. Estimated completion is 2008-01.
What conditions does trial NCT00510029 study?
This clinical trial studies the following conditions: Arrhythmia.
What interventions are being tested in trial NCT00510029?
The interventions under investigation include: GAP-134 (DRUG).
Who is sponsoring clinical trial NCT00510029?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00510029 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arrhythmia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00510029's enrollment target sits among peer trials
72 13th of 16 higher than 4 of 16 other Arrhythmia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arrhythmia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
-
Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation
RECRUITING · NA
-
Aveir AR Coverage With Evidence Development (CED) Study
RECRUITING
-
Ambulatory Surgical Center Implantable Cardioverter-Defibrillator Outcomes Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia